Trial · NCT00654732
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
NCT00654732, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2020-02-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma. Trials, record NCT00654732. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00654732
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
- NCT number
- NCT00654732
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 58 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Interventions
- Bleomycin, Dacarbazine, Doxorubicin Hydrochloride, Rituximab, Vinblastine
- First posted
- 2008-04-09
- Last updated
- 2020-02-28
- Results first posted
- 2020-02-28
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free Survival (EFS) Rate | From the start of study treatment up to 3 years | EFS will be estimated using the Kaplan-Meier method. The log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be utilized to include multiple covariates in the time-to-event analysis. Logistic regression will be utilized to assess the effect of patient prognostic factors on the response rate. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Event-free Survival (EFS) Rate | From the start of study treatment up to 3 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event-free Survival (EFS) Rate | RABVD | 17 | Participants | ||
| Event-free Survival (EFS) Rate | ABVD | 20 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | RABVD | 26 | |
| Overall Study | STARTED | ABVD | 32 | |
| Overall Study | COMPLETED | RABVD | 22 | |
| Overall Study | COMPLETED | ABVD | 26 | |
| Overall Study | NOT COMPLETED | RABVD | 4 | |
| Overall Study | NOT COMPLETED | ABVD | 6 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Neutropennia | Blood and lymphatic system disorders | RABVD | 13 | 26 | |
| serious | Neutropennia | Blood and lymphatic system disorders | ABVD | 13 | 32 | |
| serious | Anemia | Blood and lymphatic system disorders | RABVD | 1 | 26 | |
| serious | Anemia | Blood and lymphatic system disorders | ABVD | 2 | 32 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | RABVD | 1 | 26 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | ABVD | 2 | 32 | |
| serious | Infection | Immune system disorders | RABVD | 4 | 26 | |
| serious | Infection | Immune system disorders | ABVD | 1 | 32 | |
| serious | Respiratory Complicaton | Respiratory, thoracic and mediastinal disorders | RABVD | 0 | 26 | |
| serious | Respiratory Complicaton | Respiratory, thoracic and mediastinal disorders | ABVD | 2 | 32 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | RABVD | 5 | 26 |
| Total, all-cause mortality | ABVD | 6 | 32 |
| Total, other adverse events | RABVD | 0 | 26 |
| Total, other adverse events | ABVD | 0 | 32 |
| Total, serious adverse events | RABVD | 13 | 26 |
| Total, serious adverse events | ABVD | 13 | 32 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016672 | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | KOONG, ALBERT | UNIVERSITY OF TX MD ANDERSON CAN CTR | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| RABVD vs ABVD: deaths from any cause | Trial comparisons |
| RABVD vs ABVD: Event-free Survival (EFS) Rate | Trial comparisons |
| RABVD vs ABVD: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00654732
GET https://conductscience.org/api/trials/v1/NCT00654732/registered